☆ 4.7 Article

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study

DIABETES CARE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Endocrinology & Metabolism

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial

Peter Rossing et al.

Summary: The study showed that finerenone significantly reduced the risk of kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. There was no clear interaction between GLP-1RA use and the treatment effect of finerenone, indicating consistent effects on kidney and cardiovascular outcomes regardless of GLP-1RA use.

DIABETES OBESITY & METABOLISM (2022)

添加到收藏夹

Article Urology & Nephrology

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Peter Rossing et al.

Summary: The FIDELIO-DKD study investigated the treatment effect of finerenone in patients with CKD and T2D, showing that finerenone can improve UACR and have beneficial effects on kidney and cardiovascular outcomes, regardless of whether patients were also using SGLT-2i.

KIDNEY INTERNATIONAL REPORTS (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes

Gerasimos Filippatos et al.

Summary: The FIDELIO-DKD trial demonstrated that Finerenone reduced the incidence of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes, with a composite outcome including cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. There was no difference in the treatment effect based on preexisting cardiovascular disease status, with similar incidence of adverse events between treatment arms.

CIRCULATION (2021)

添加到收藏夹

Article Endocrinology & Metabolism

6. Glycemic Targets: Standards of Medical Care in Diabetes-2021

Summary: The ADA Standards of Medical Care in Diabetes offers recommendations and guidelines for diabetes care, with updates made by a multidisciplinary expert committee annually. Readers are invited to provide feedback on the standards through the professional website.

DIABETES CARE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021

Summary: The American Diabetes Association (ADA) Standards of Medical Care in Diabetes provides clinical practice recommendations, treatment goals, and tools for evaluating care quality for diabetes patients. The ADA Professional Practice Committee is responsible for updating these standards, and readers can provide feedback on the standards on the website.

DIABETES CARE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial

Joao Pedro Ferreira et al.

Summary: The study findings suggest that patients with heart failure with reduced ejection fraction and insulin-treated diabetes benefit more from eplerenone compared to those with diabetes not treated with insulin and individuals without diabetes.

CIRCULATION-HEART FAILURE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey

Deval Gor et al.

JOURNAL OF DIABETES (2020)

添加到收藏夹

Article Endocrinology & Metabolism

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

John B. Buse et al.

DIABETOLOGIA (2020)

添加到收藏夹

Article Medicine, General & Internal

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis A Multicenter Cohort Study

Antonios Douros et al.

ANNALS OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Development of Risk Prediction Equations for Incident Chronic Kidney Disease

Robert G. Nelson et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

添加到收藏夹

Article Urology & Nephrology

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

George L. Bakris et al.

AMERICAN JOURNAL OF NEPHROLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

Luis M. Ruilope et al.

AMERICAN JOURNAL OF NEPHROLOGY (2019)

添加到收藏夹

Review Medicine, General & Internal

A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis

Sandra Korol et al.

MEDICINE (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON

Muh Geot Wong et al.

DIABETES CARE (2016)

添加到收藏夹

Review Peripheral Vascular Disease

Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials

Jie V. Zhao et al.

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2016)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment-patterns-NHANES 2007-2012

Bingcao Wu et al.

BMJ OPEN DIABETES RESEARCH & CARE (2016)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Endocrinology & Metabolism

Link between insulin resistance and hypertension: What is the evidence from evolutionary biology?

Ming-Sheng Zhou et al.

DIABETOLOGY & METABOLIC SYNDROME (2014)

添加到收藏夹

Article Urology & Nephrology

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

Vlado Perkovic et al.

KIDNEY INTERNATIONAL (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure

Masayuki Yamaji et al.

AMERICAN HEART JOURNAL (2010)

添加到收藏夹

Article Medicine, General & Internal

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

Faramarz Ismail-Beigi et al.

LANCET (2010)

添加到收藏夹

Article Medicine, General & Internal

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Anushka Patel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Article Urology & Nephrology

Progression of nephropathy in type 2 diabetic patients

K Rossing et al.

KIDNEY INTERNATIONAL (2004)

添加到收藏夹

Article Endocrinology & Metabolism

When oral agents fail: practical barriers to starting insulin

M Korytkowski

INTERNATIONAL JOURNAL OF OBESITY (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.